From the study design link I posted earlier:
Hematopoietic Stem Cell Transplant
Rationale: A reduced regenerative capacity of stem cells is widely believed to contribute to age-related morbidity and functional tissue decline. Numerous studies have shown stem cell transplantation to have rejuvenating effects in mouse tissues, and several additionally show a lifespan extension effect [PMID 32012439, 31031800].
Design: The study design is largely (but see below) based on the protocol utilized by Guderyon et al. 2020 [PMID 32012439] and consists of mobilizing the recipient bone marrow niche followed by transplant of lineage-depleted hematopoietic stem cells (HSCT).
Bone Marrow: We have opted to use lineage-depleted bone marrow HSCs as opposed to additional selection for and expansion of long-term self-renewing HSCs. This was on the basis that 1) prior lifespan studies used whole or lineage-depleted bone marrow, which may include MSCs or other beneficial cells promoting engraftment, and 2) expansion protocols have not been extensively validated.
Mobilization Protocol: We will follow the mobilization protocol for recipient mice as outlined in Guderyon 2020, consisting of G-CSF + AMD3100. Although other newer mobilization reagents require fewer injections, efficacy is not well established; the current protocol is most common for chemical mobilization, has been used in aged mice, and remains the current standard of care for mobilizing HSCs from human BM donors.
# of cells: Each administration will consist of ~2x10⁷ HSCs, derived from 8 sex-matched C57Bl/6J PEP-BOY (CD45.2) donor mice per injection. This number is four-fold greater than the Guderyon study, however in line with other HSCT studies [PMID 31031800, 18491294]. Additionally, it is demonstrated that % donor cell engraftment is largely based on competition with mobilized recipient cells; thus, increasing the donor to recipient ratio in the blood may allow for increased engraftment with each administration allowing for fewer transplants overall and thus less stress on the animals.
Number of Transplant Injections: While the lifespan cohort of the Guderyon study received a total of 8 HSCTs, each round administered only 5x10⁶ lineage-negative (long-term repopulating) donor cells. We wish to minimize the number of administrations for each mouse. Therefore, we will perform 2 rounds of HSCT, a month apart, and then assess the % donor-derived cells (CD45.2) in peripheral blood after 4-8 weeks (timing to coincide with planned blood draw). Whether or not additional rounds of HSCT are performed (for a given experimental group) will be decided based on percentage engraftment in recipient mice.
5 Likes
jakexb
#21
Wow, I would not have seen that one coming as a contender
1 Like
Lost
#23
Heh. I don’t know how to interpret that. The all interventions except gene therapy survival is terrible in males, but the other things don’t agree. So presumably one needs to dig deeper into the error ranges.
2 Likes
Actually, that’s a pretty smart way of doing this. Maybe they should administer Rapa and have the mice exercise and then gauge the effectiveness of treatments.
1 Like
Great stuff! Keep us aprised of the developments. Thank you so much for sharing these amazing results with us!
1 Like
Amazing. For males, most of the benefit is from rapamycin but additional benefit can be obtained AND it appears that no detriment is caused by adding any of the tested interventions (additive even if small). Perhaps the interventions do not overlap on mechanisms enough to cause an overload. I look forward to learning more about this.
3 Likes
Neo
#31
And there is what look like a robust study, by a separate and good group in a good journal showing longevity benefits of HSCs that I had missed
… done without radiation or other toxic ways to prorate for them
Haven’t look at the paper carefully yet, but find it very exciting
Interestingly these results are in female mice even if they expect the effects to be larger in males
With age, stem cells diminish in their ability to regenerate adult tissues, likely contributing to age-related morbidity. Thus, we replaced aged hematopoietic stem cells (HSCs) with young-donor HSCs using a novel mobilization-enabled hematopoietic stem cell transplantation (HSCT) technology as an alternative to the highly toxic conditioning regimens used in conventional HSCT. Using this approach, we are the first to report an increase in median lifespan (12%) and a decrease in overall mortality hazard (HR: 0.42, CI: 0.273–0.638) in aged mice following transplantation of young-donor HSCs. The increase in longevity was accompanied by reductions of frailty measures and increases in food intake and body weight of aged recipients. Young-donor HSCs not only preserved youthful function within the aged bone marrow stroma, but also at least partially ameliorated dysfunctional hematopoietic phenotypes of aged recipients. This compelling evidence that mammalian health and lifespan can be extended through stem cell therapy adds a new category to the very limited list of successful anti-aging/life-extending interventions. Our findings have implications for further development of stem cell therapies for increasing health and lifespan.
https://onlinelibrary.wiley.com/doi/10.1111/acel.13110
2 Likes
Neo
#33
What would you say the main 2 takeaways are?
It is quite hard to follow and I got it wrong the first time.
I think this is the study page
It looks like all the interventions apart from GalNav are very slightly better than All the Interventions.
Gal Nav may be worse than control.
Rapamycin is the most effective single intervention, but adding others apart from GalNav can make things better although hematopoietic stem cell transplantation may not make things better and might make things worse.
4 Likes
Very interesting results! I think it confirms that Gal-Nav may not be that useful, even in combination with other therapies (as well as possibly other senolytics). It makes me seriously reconsider using senolytics.
It does reinforce the fact that a combination of therapies work together to provide optimal lifespan. This is good news for the ‘everything and the kitchen sink’ approach.
Keep the updates coming!!! 
1 Like
I think there is confusion of senolytics which comes from confusion over senescent cells. I think a lot of senescent cells are cells which have got stuck and failed to differentiate properly (because of a mixture of bad mitochondria and IL-10). Hence the best solution is to get them to differentiate rather than to kill them.
Interestingly macrophages are known at times to try to donate mitochondria to cells which appear to have issues (specifically cancer cells, but probably also other cells).
1 Like
Neo
#39
I think they carefully thought through which specific (and limited number) of things to try and combine based on those thing likely not having interfering interactions.
I agree that it it suggests that certain carefully combined therapies can be beneficial in an additive way
but it has hardly at all addressed that there can be big risks and def “negative synergies” of combining things that have not been studied in combinations
2 Likes
Neo
#40
1 Like
